ANUH PHARMA
|
ANUH PHARMA Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 11.98 | 7.22 | 6.10 | 5.67 | 5.71 |
| CEPS(Rs) | 13.70 | 9.16 | 8.49 | 8.68 | 4.26 |
| DPS(Rs) | 2.50 | 2.00 | 1.75 | 1.50 | 2.75 |
| Book NAV/Share(Rs) | 58.11 | 48.14 | 42.66 | 38.04 | 64.74 |
| Tax Rate(%) | 23.31 | 23.78 | 21.88 | 26.24 | 25.32 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.65 | 9.78 | 9.67 | 10.25 | 7.31 |
| EBIT Margin(%) | 12.19 | 9.10 | 8.29 | 9.22 | 6.42 |
| Pre Tax Margin(%) | 12.04 | 8.96 | 7.97 | 8.75 | 6.03 |
| PAT Margin (%) | 9.24 | 6.83 | 6.22 | 6.46 | 4.50 |
| Cash Profit Margin (%) | 10.56 | 8.66 | 8.66 | 9.88 | 6.71 |
| Performance Ratios | |||||
| ROA(%) | 14.14 | 9.63 | 8.99 | 8.63 | 5.06 |
| ROE(%) | 22.56 | 15.90 | 15.11 | 16.12 | 8.75 |
| ROCE(%) | 29.66 | 21.05 | 19.33 | 19.75 | 10.87 |
| Asset Turnover(x) | 1.53 | 1.41 | 1.44 | 1.34 | 1.12 |
| Sales/Fixed Asset(x) | 6.37 | 5.31 | 4.97 | 4.55 | 5.20 |
| Working Capital/Sales(x) | 3.54 | 3.62 | 3.84 | 4.48 | 5.28 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.16 | 0.19 | 0.20 | 0.22 | 0.19 |
| Receivable days | 101.36 | 105.71 | 90.17 | 77.87 | 89.32 |
| Inventory Days | 41.55 | 52.54 | 59.98 | 59.23 | 59.91 |
| Payable days | 110.65 | 125.45 | 117.42 | 125.15 | 130.55 |
| Valuation Parameters | |||||
| PER(x) | 20.49 | 11.03 | 14.09 | 15.91 | 10.21 |
| PCE(x) | 17.93 | 8.70 | 10.13 | 10.40 | 13.69 |
| Price/Book(x) | 4.23 | 1.65 | 2.01 | 2.37 | 1.80 |
| Yield(%) | 1.02 | 2.51 | 2.04 | 1.66 | 2.36 |
| EV/Net Sales(x) | 1.89 | 0.74 | 0.86 | 1.03 | 1.09 |
| EV/Core EBITDA(x) | 13.92 | 6.77 | 7.94 | 8.01 | 12.17 |
| EV/EBIT(x) | 15.43 | 8.14 | 10.27 | 10.99 | 16.37 |
| EV/CE(x) | 4.17 | 1.63 | 1.20 | 1.34 | 1.02 |
| M Cap / Sales | 1.90 | 0.76 | 0.89 | 1.05 | 0.95 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 22.66 | 8.39 | 12.66 | 40.72 | -4.27 |
| Core EBITDA Growth(%) | 51.68 | 9.98 | -5.38 | 102.79 | -20.82 |
| EBIT Growth(%) | 64.40 | 18.46 | 0.30 | 98.80 | -38.14 |
| PAT Growth(%) | 66.00 | 18.38 | 7.47 | 98.78 | -38.78 |
| EPS Growth(%) | 66.00 | 18.38 | 7.47 | -0.61 | -38.78 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | - | 0.01 | 0.07 | 0.27 |
| Current Ratio(x) | 2.20 | 1.91 | 1.98 | 1.70 | 1.37 |
| Quick Ratio(x) | 1.71 | 1.46 | 1.37 | 1.12 | 0.99 |
| Interest Cover(x) | 82.82 | 64.61 | 25.76 | 19.99 | 16.23 |
| Total Debt/Mcap(x) | - | - | 0.01 | 0.03 | 0.15 |
Compare Financial Ratios of peers of ANUH PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ANUH PHARMA | ₹1,079.9 Cr | -2.2% | 9.1% | 52.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹441,838.0 Cr | 1% | 0.7% | 47.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,107.0 Cr | -1.1% | -5.8% | 61.7% | Stock Analytics | |
| CIPLA | ₹120,270.0 Cr | 0.3% | -1.8% | 19.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹113,077.0 Cr | 6% | 11.8% | 20.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,553.2 Cr | -1.5% | -0.1% | 47% | Stock Analytics | |
ANUH PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ANUH PHARMA | -2.2% |
9.1% |
52.5% |
| SENSEX | -2.1% |
-2% |
11.3% |
You may also like the below Video Courses
